Patent 11419823

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

Active provider: Google · gemini-2.5-flash

Ownership chain (3)

Asserters network →

Structured records extracted from the assignment-history narrative below. Each entity links to its full ownership-network profile.

2021-03-17 · reel 056461/0817 · Assignment
VELOXIS PHARMACEUTICALS A/S VELOXIS PHARMACEUTICALS INC.
Correspondent: Jeffrey M. Belson · GlaxoSmithKline
Internal reorganization
2021-04-02 · reel 056461/0818 · Assignment
VELOXIS PHARMACEUTICALS A/S VELOXIS PHARMACEUTICALS INC.
Correspondent: Jeffrey M. Belson · GlaxoSmithKline
Internal reorganization
2024-06-07 · reel 063073/0675 · Change of Name
VELOXIS PHARMACEUTICALS INC.VELOXIS PHARMACEUTICALS INC.
Correspondent: Jeffrey M. Belson · GlaxoSmithKline
Change of address for the assignee

Assignment history

✓ Generated

Inventors

Nikolaj Skak: Veloxis Pharmaceuticals Inc.
Per Holm: Veloxis Pharmaceuticals Inc.

Both inventors were employed by the original assignee, Veloxis Pharmaceuticals Inc., at the time of the patent's priority date (2008-05-30) and filing date (2018-11-13).

Original assignee

Veloxis Pharmaceuticals Inc. is the original assignee. Veloxis Pharmaceuticals is a pharmaceutical company focused on the development and commercialization of therapeutics for organ transplant patients, including products embodying tacrolimus, such as Envarsus XR (tacrolimus extended-release tablets). Veloxis Pharmaceuticals Inc. is currently operating.

Assignment timeline

The USPTO Assignment Center (https://assignmentcenter.uspto.gov/) shows the following assignments for US patent 11,419,823:

2021-03-17 (executed) / recorded 2021-03-17 — Reel 056461/0817
- Conveyance: Assignment
- Assignor: VELOXIS PHARMACEUTICALS A/S
- Assignee: VELOXIS PHARMACEUTICALS INC.
- Correspondent: Jeffrey M. Belson of GlaxoSmithKline, 1500 Rittenhouse Road, Collegeville, PA, 19426, US. This correspondent appears for GlaxoSmithKline related entities.
- Context: Internal reorganization
2021-04-02 (executed) / recorded 2021-04-02 — Reel 056461/0818
- Conveyance: Assignment
- Assignor: VELOXIS PHARMACEUTICALS A/S
- Assignee: VELOXIS PHARMACEUTICALS INC.
- Correspondent: Jeffrey M. Belson of GlaxoSmithKline, 1500 Rittenhouse Road, Collegeville, PA, 19426, US. This correspondent appears for GlaxoSmithKline related entities.
- Context: Internal reorganization
2024-06-07 (executed) / recorded 2024-06-07 — Reel 063073/0675
- Conveyance: Change of Name
- Assignor: VELOXIS PHARMACEUTICALS INC.
- Assignee: VELOXIS PHARMACEUTICALS INC.
- Correspondent: Jeffrey M. Belson of GlaxoSmithKline, 1500 Rittenhouse Road, Collegeville, PA, 19426, US. This correspondent appears for GlaxoSmithKline related entities.
- Context: Change of address for the assignee

Timeline diagram

timeline
    title Ownership of US 11419823
    2008 : Priority claimed
    2018 : Application filed by Veloxis
    2021 : Assigned to Veloxis Pharm Inc
         : Assigned to Veloxis Pharm Inc
    2022 : Patent granted
    2024 : Change of Address for Veloxis

NPE / troll-pattern signals

Shell-entity transfer — not present. The assignments are between Veloxis Pharmaceuticals A/S and Veloxis Pharmaceuticals Inc., indicating an internal corporate restructuring rather than a transfer to a shell entity.
Known asserter in the chain — not present. Veloxis Pharmaceuticals Inc. is an operating company.
Repeat correspondent across the chain — present. Jeffrey M. Belson of GlaxoSmithKline is listed as the correspondent for all recorded assignments (Reel 056461/0817, Reel 056461/0818, Reel 063073/0675). This attorney is a repeat-player, handling recordings for GlaxoSmithKline-related entities.
Cascading transfers — not present. The two assignments in 2021 are very close in time, but appear to be part of a single internal reorganization from Veloxis Pharmaceuticals A/S to Veloxis Pharmaceuticals Inc., not a chain through multiple distinct shell LLCs.
Pre-litigation transfer — unclear. While there are litigation events noted for the patent family (starting in 2024 and 2025), the assignments occurred in 2021, well before the documented litigation dates. It's possible the litigation refers to an earlier stage or other patents in the family, but based solely on the provided information for this specific patent, the transfers are not immediately pre-litigation.
Bankruptcy fire-sale — not present. There is no indication of bankruptcy in the assignment records or patent metadata.
Privateering — not present. Veloxis Pharmaceuticals Inc. is the current assignee and an operating company.
Defensive aggregator (anti-NPE) — not present. The chain does not terminate at a defensive aggregator.

Verdict

Operating-company assertion. The patent remains with Veloxis Pharmaceuticals Inc., an operating company that markets products related to tacrolimus. The assignments recorded (Reel 056461/0817, Reel 056461/0818) appear to be part of an internal corporate reorganization, not a transfer to a non-practicing entity. The patent is currently involved in litigation, suggesting assertion by the operating company against competitors.

USPTO Assignment Center search page for US11419823: https://assignmentcenter.uspto.gov/detail-result-view/?id=[91040854](/patent/91040854)-3406-4448-b4b1-8b21c430e702

Generated 5/30/2026, 6:48:17 AM